Currently out of the existing stock ratings of Liisa Bayko, 123 are a BUY (87.23%), 18 are a HOLD (12.77%).

Liisa Bayko

Work Performance Price Targets & Ratings Chart

Analyst Liisa Bayko, currently employed at EVERCORE, carries an average stock price target met ratio of 43.06% that have a potential upside of 49.38% achieved within 236 days.

Liisa Bayko’s has documented 296 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 08-May-2025.

Wall Street Analyst Liisa Bayko

Analyst best performing recommendations are on AVTE (AEROVATE THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 1/9/2018. The price target of $60 was fulfilled within 3 days with a profit of $3.85 (6.86%) receiving and performance score of 22.86.

Average potential price target upside

of $59.38 (73.95%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $30.4 (16.25%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $24.4 (45.25%) on RARE (ULTRAGENYX).

ABUS Arbutus Biopharma Corp AIMT Aimmune Therapeutics BCRX BioCryst Pharmaceuticals CRSP Crispr Therapeutics AG ENTA Enanta Pharmaceuticals ICPT Intercept Pharmaceuticals INSM Insmed KNSA Kiniksa Pharmaceuticals Ltd RARE Ultragenyx SRPT Sarepta Therapeutics ACHN Achillion Pharmaceuticals EDIT Editas Medicine INCY yte MDGL Madrigal Pharmaceuticals TVTX Travere Therapeutics VRTX Vertex Pharmaceuticals PRQR ProQR Therapeutics BV AKRO Akero Therapeutics ALT Altimmune AURA Aura Biosciences CNCE Concert Pharmaceuticals CRBP Corbus Pharmaceuticals RTRX Travere Therapeutics VERA Vera Therapeutics ANTX AN2 Therapeutics ALNY Alnylam Pharmaceuticals AVTE Aerovate Therapeutics ETNB 89bio SVRA Savara

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Keay Nakae (CHARDAN CAPITAL)